ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

Valeant To Buy Branded Generics Assets From Gerot Lannach

DOW JONES NEWSWIRES Valeant Pharmaceuticals International Inc. (VRX) said Tuesday it's acquiring from Austria's Gerot Lannach certain branded generics assets that generate the bulk of their sales in Russia. Mississauga, Ont.-based Valeant said the assets generated net revenue of about $55 million last year. Gerot Lannach's largest product is acetylsalicylic acid, a low-dose aspirin. Valeant said it will pay less than three times sales, and may make up to an additional $20 million in milestone payments, based upon future performance objectives. As part of the transaction, Valeant and Gerot Lannach will enter into a strategic partnership that includes an exclusive 10-year supply agreement for the acquired products and the opportunity for Valeant to introduce additional Gerot Lannach products into Valeant territories such as its emerging markets in Southeast Asia and Latin America. Valeant expects the transaction to boost results starting immediately. -By Carolyn King, Dow Jones Newswires; 416-306-2100; carolyn.m.king@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
07/26/201608:30:00Progenics Receives $50 Million Milestone Payment Following FDA...
07/22/201617:00:00Toronto Stocks Rise as Earnings Offset Falling Oil and Gold Prices
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/22/201602:00:00Valeant Pharmaceuticals Receives Complete Response Letter From...
07/19/201621:40:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201621:02:00Valeant Gets FDA OK for Anticonstipation Tablets Developed by...
07/19/201619:19:00Valeant, Progenics Shares Rise on Constipation Drug Approval
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201618:04:00Valeant and Progenics Announce FDA Approves RELISTOR® Tablets...
07/19/201617:48:00Valeant Gets FDA Panel Recommendation for Psoriasis Drug
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/19/201616:27:00FDA Advisory Committee Recommends Approval Of Brodalumab For...
07/18/201601:00:00Pharming Announces Positive Results from Randomized Controlled...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/15/201608:00:00Valeant Pharmaceuticals Announces Second Quarter Results Conference...
07/14/201609:43:00Valeant's Ex-CEO Michael Pearson Sells Nearly $100 Million in...
07/14/201608:50:00Valeant Pharmaceuticals Comments On Recent Stock Transactions
07/14/201608:50:00Valeant Pharmaceuticals Comments On Recent Stock Transactions
07/14/201603:04:00Pearson Sells Large Valeant Stake -- WSJ
07/14/201601:00:00PHARMING Amends RUCONEST Distribution Agreement with SOBI

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad